NXTC, US65343E2072

NextCure seeks court validation of 1-for-12 split: NextCure stock faces November 6 hearing

Published on 10/16/2026 at 04:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Court hearing: November 6, 2026, at 3:00 p.m. ET. NextCure stock last stood at USD 6.88 on October 15, 2026, at a USD 31.5 million value.

Legal review and valuation

NextCure filed its court petition on September 14, 2026, over a 1-for-12 reverse split.
The July 14, 2026, merger filing cited 4,068,951 shares outstanding.
NextCure stock had a USD 31.5 million market value as of October 15, 2026.

NXTC, US65343E2072, Illustration mit AI erstellt.

NextCure is seeking court validation of its 1-for-12 reverse split, a legal issue that could affect the company's proposed combination with Avere Therapeutics. The September 21, 2026, filing set a Delaware Court of Chancery hearing for November 6, 2026, at 3:00 p.m. Eastern Time, according to StockTitan.

Why the split needs review

NextCure filed the petition on September 14, 2026, after amendments to Delaware law created uncertainty over whether a supermajority voting standard should have applied to the 2025 reverse split. The company said an unsuccessful petition could delay or prevent the Avere transaction, according to StockTitan.

The filing says the 1-for-12 split became effective on July 14, 2025. At the 2025 annual meeting, 18,166,577 votes supported the amendment out of 20,202,136 votes cast, equal to 89.92 percent of votes cast and 64.76 percent of outstanding shares.

What does the court test mean?

The legal review matters because the July 14, 2026, merger agreement relied on a post-split capitalization of 4,068,951 shares. NextCure is a clinical-stage biotechnology company developing immunomedicines for cancer and other immune-related diseases, according to NextCure.

Three dated developments

On July 14, 2026, NextCure filed that it had entered a merger agreement with Avere and cited 4,068,951 shares in the transaction documents. On September 14, 2026, it filed the Section 205 petition over the 1-for-12 reverse split. On September 21, 2026, the court ordered the November 6 hearing at 3:00 p.m. Eastern Time. Each event is detailed in the StockTitan filing.

Dates for shareholders

Written submissions regarding the petition are due by October 27, 2026. The Delaware court hearing follows on November 6, 2026, at 3:00 p.m. Eastern Time.

Stock trades on Nasdaq

NextCure's last available Nasdaq price was USD 6.88 on October 15, 2026, at 4:00 p.m. Eastern Time. Its market capitalization was USD 31.5 million on the same date, keeping the court decision and the merger timetable central to the stock's near-term narrative.